Knobias Clip Report (09-22-2008) JAV
Submitted By Knobias ClipReport
JAV: Presents Company’s Focus and Commercial Strategy at UBS Conference Today
By Fain Hughes, fhughes@knobias.com
The CEO of Javelin Pharmaceuticals, Inc. (JAV), Martin J. Driscoll, presented today at the UBS Global Life Sciences Conference in New York, NY.
Javelin develops new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. The Company has one marketed drug in the UK and three drug candidates in U.S. Phase 3 clinical development. The products include Dyloject(TM), in development in the U.S. for the treatment of post-operative pain and in Europe for acute forms of pain. Ereska(TM)(intranasal ketamine) is currently under development for treatment of acute moderate-to-severe pain. Rylomine(TM)(intranasal morphine) represents such an alternative formulation that combines patient convenience, ease of use, and cost-effectiveness with the rapid onset of pain relief and the well-accepted potency of injectable delivery routes.
Mr. Drisoll explained, “There is a significant medical needs in the pain market. Much of the market is moving away from opiates. There is also a strong trend toward outpatient surgeries. Our product profolio works well for this. They provide flexibility, rapid onset of action and the lower adverse event profile fits this trend well.”
Explaining recent changes at the Company, Mr. Driscoll commented, “Since our management change in March, we have instituted significant change. There is a greater sharholder focus in the Company. In particular, we are focused on delivering on our clinical and regulatory timelines. We also fundamentally changed the commercialization strategy of the Company. The Company had moved forward to commercialize all of the agents on its own on a global basis. I pulled the Company back and determined that will be a great late stage pain development company and commercialized over time. We will work with Pharma to commercialize our agents to withstand the commercialization risks that are very common with new introductions in the marketplace. We are now well positioned for growth.”
Visit 1800blogger to see all of our industry leading blogs.
